ORIGINAL RESEARCH | MEDICAL GENETICS

ASSOCIATIONS BETWEEN SNPS IN THE GENES ENCODING UROKINASE SYSTEM PROTEINS AND THE RISK OF PLACENTAL INSUFFICIENCY

Revina DB^{1 🖾}, Balatskiy AV^{1,2}, Larina EB³, Oleynikova NA¹, Mishurovsky GA¹, Malkov PG¹, Samokhodskaya LM¹, Panina OB¹, Tkachuk VA^{1,2}

¹ Lomonosov Moscow State University, Moscow, Russia

² National Medical Research Center of Cardiology, Moscow, Russia

³ Lapino Clinical Hospital "Mother and Child", Moscow, Russia

Placental insufficiency (Pl) and its complications are multifactorial conditions that cause perinatal morbidity and mortality. Since the urokinase system is involved in placentation, it should have a role in Pl pathogenesis. The aim of this work was to study the associations between single nucleotide polymorphisms (SNPs) of genes coding for protein components of the urokinase system and Pl, as well as investigate their effect on the expression of these proteins in the placenta and placental structure. We examined 114 women with uncomplicated pregnancy and delivery, 48 female patients with pre-eclampsia and/or intrauterine growth restriction (IUGR), and 95 newborns, (pre-eclampsia and/or IUGR: n = 60; uncomplicated pregnancy and delivery: n = 35). Maternal and fetal DNAs were genotyped using real-time PCR. Placenta fragments were subjected to morphometry and immunohistochemistry. We discovered the associations between Pl and the maternal C allele of rs4065 (Pl group: CC-CT 64.1%, TT 35.9%; controls: CC-CT 25.6%, TT 74.49%; OR (95%Cl): 6.83 (2.63–17.79)), the maternal A allele of rs2302524 (GG-GA 20.5%, AA 79.5% vs. GG-GA 48.1%, AA 51.9%, OR (95%Cl): 0.27 (0.1–0.71)), the fetal C allele of rs4065 (CC-CT 76.4 %, TT 23.6% vs. CC-CT 69.6%, TT 30.4%, OR (95%Cl): 1.37 (0.45–4.17)), and the fetal C allele of rs344781 (TT-TC 69.1%, CC 30.9% vs. TT-C 95.7%, CC 4.3%, OR (95% Cl): 5.02 (1.07–23.6)). The multivariate analysis confirmed the significance of the fetal rs4065 genotype. In patients with Pl, uPA expression was lower (ME (95%Cl): 116.45 (100.5; 128.74) vs. 126.09 (113.76; 139.19); p < 0.05). No associations were established between SNPs and protein expression. The degree of vascularization depended on the maternal rs4065 genotype (the stroma-to-vessel ratio for the CC genotype was 0.17 (0.15; 0.19); for the CT genotype, 0.18 (0.15; 0.21) and for the TT genotype, 0.23 (0.2; 0.27); p < 0.05). We conclude that high placental uPA and the presence of the fetal TT rs4065 genotype are protective against the risk

Keywords: pre-eclampsia, intrauterine growth restriction, placental insufficiency, urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, single nucleotide polymorphism, angiogenesis

Funding: this study was conducted under the state assignment for Lomonosov MSU using the equipment acquired as part of the Scientific Development Program of Lomonosov MSU.

Acknowledgement: the authors thank Mamedov NN, PhD Med, an Assistant Professor at the Department of Obstetrics and Gynecology (Faculty of Fundamental Medicine, Lomonosov MSU) for his help in creating the collection of biosamples (umbilical cord and placenta fragments, blood samples).

Author contribution: Revina DB, Balatskiy AV, Larina EB, Samokhodskaya LM, Panina OB, Tkachuk VA — study design; Revina DB, Balatskiy AV, Larina EB, Oleynikova NA, Mishurovsky GA — collection and processing of biosamples and clinical datal; Revina DB, Balatskiy AV, Mishurovsky GA — statistical analysis; Revina DB, Balatskiy AV — interpretation of the results; Revina DB, Balatskiy AV, Oleynikova NA, Mishurovsky GA — manuscript preparation; Malkov PG, Samokhodskaya LM, Panina OB, Tkachuk VA — manuscript revision; Revina DB and Balatskiy AV equally contributed to the study.

Compliance with ethical standards: the study was approved by the Ethics Committee of Lomonosov MSU (Protocol 4 dated June 4 2018). All patients gave informed consent to participate.

Correspondence should be addressed: Daria B. Revina

Lomonosovsky prospect, 27, k.1, Moscow, 119192; lozinskaya.daria@gmail.com Received: 31.10.2019 Accepted: 18.11.2019 Published online: 07.12.2019 DOI: 10.24075/brsmu.2019.076

АССОЦИАЦИЯ SNP ГЕНОВ БЕЛКОВ УРОКИНАЗНОЙ СИСТЕМЫ С РАЗВИТИЕМ ПЛАЦЕНТАРНОЙ НЕДОСТАТОЧНОСТИ

Д. Б. Ревина¹ 🖾, А. В. Балацкий^{1,2}, Е. Б. Ларина³, Н. А. Олейникова¹, Г. А. Мишуровский¹, П. Г. Мальков¹, Л. М. Самоходская¹, О. Б. Панина¹, В. А. Ткачук^{1,2} ¹ Московский государственный университет имени М. В. Ломоносова, Москва, Россия

² Национальный медицинский исследоваельский центр кардиологии, Москва, Россия

³ Клинический госпиталь Лапино «Мать и дитя», Москва, Россия

Плацентарная недостаточность (ПН) и ее осложнения — многофакторные заболевания, ведущие к перинатальной заболеваемости и смертности. Урокиназная система задействована в формировании плаценты и может быть рассмотрена как участник патогенеза ПН. Целью работы было исследовать ассоциацию однонуклеотидных полиморфизмов (SNP) генов белков урокиназной системы с развитием ПН, их влияние на экспрессию соответствующих белков в плаценте и ее строение. Обследованы 114 женщин с физиологическим течением беременности и родов и 48 пациенток с преэклампсией и/или задержкой роста плода (ЗРП), 95 новорожденных детей (беременность с преэклампсией и/или ЗРП — 60, физиологическое течение беременности и родов — 35). Проведено генотипирование при помощи ПЦР в реальном времени, морфометрическое и иммуногистохимическое исследования фрагментов плацент. Выявлены ассоциации между развитием ПН и наличием у матери — аллеля C rs4065 (в группе ПН — CC-CT 64,1%, TT 35,9%, в контрольной группе — CC-CT 25,6%, TT 74,49%, ОШ (95% ДИ) — 6,83 (2,63–17,79)), аллеля A rs2302524 (GG-GA 20,5%, AA 79,5% против GG-GA 48,1%, AA 51,9%, ОШ (95% ДИ) — 0,27 (0,1–0,71)), у плода — аллеля C rs4065 (CC-CT 76,4 %, TT 23,6% против CC-CT 69,6%, TT 30,4%, ОШ (95% ДИ) — 1,37 (0,45–4,17)), аллеля C rs344781 (ПТ-TC 69,1%, CC 30,9% против TT-C 95,7%, CC 4,3%, ОШ (95% ДИ) — 5,02 (1,07–23,6)). Многофакторный анализ подтвердил значимость генотипа плода по rs4065. Экспрессия иРА была ниже при ПН (медиана (95% ДИ) — 116,45 (100,5; 128,74) против 126,09 (113,76; 139,19); p < 0,05). Ассоциации SNP с экспрессией белков выявлено не было. Васкуляризация зависела от генотипа матери по rs4065 (стромальнососудистое соотношение при генотипа сС — 0,17 (0,15; 0,19), СТ — 0,18 (0,15; 0,21), TT — 0,23 (0,2; 0,27); p < 0,05). Таким образом, высокий уровень иРА в плаценте и наличие генотипа rs4065 TT у плода носят протективный характер в отношении развития ПН.

Ключевые слова: преэклампсия, задержка роста плода, плацентарная недостаточность, активатор плазминогена урокиназного типа, рецептор активатора плазминогена урокиназного типа, однонуклеотидный полиморфизм, ангиогенез

Финансирование: исследование выполнено в рамках государственного задания МГУ имени М. В. Ломоносова и с использованием оборудования, приобретенного по программе научного развития МГУ имени М. В. Ломоносова.

Благодарности: ассистенту кафедры акушерства и гинекологии факультета фундаментальной медицины МГУ имени Ломоносова, к. м. н. Николаю Назимовичу Мамедову за помощь в создании коллекции биоматериалов (фрагментов последов, образцов крови).

Информация о вкладе авторов: Д. Б. Ревина, А. В. Балацкий, Е. Б. Ларина, Л. М. Самоходская, О. Б. Панина и В. А. Ткачук — дизайн исследования; Д. Б. Ревина, А. В. Балацкий, Е. Б. Ларина, Н. А. Олейникова, Г. А. Мишуровский — сбор и обработка биоматериала, клинических данных; Д. Б. Ревина, А. В. Балацкий, Г. А. Мишуровский — статанализ; Д. Б. Ревина, А. В. Балацкий — интерпритация результатов; Д. Б. Ревина, А. В. Балацкий, Г. А. Мишуровский — статанализ; Д. Б. Ревина, А. В. Балацкий, — интерпритация результатов; Д. Б. Ревина, А. В. Балацкий, Г. А. Мишуровский, П. А. Мишуровский, П. А. Мишуровский, П. А. Мишуровский, П. А. Мишуровский, Н. А. Олейникова — написание рукописи; П. Г. Мальков. Л. М. Самоходская, О. Б. Панина, В. А. Ткачук — редактирование рукописи. Вклады Д. Б. Ревиной и А. В. Балацкого равноценны.

Соблюдение этических стандартов: исследование одобрено этическим комитетом Медицинского научно-образовательного центра МГУ имени М. В. Ломоносова (протокол № 4 от 4 июня 2018 г.). Все пациенты подписали добровольное информированное согласие на включение в исследование. Я для корреспонденции: Дарья Борисовна Ревина

Ломоносовский проспект, д. 27, корп. 1, г. Москва, 119192; lozinskaya.daria@gmail.com

Статья получена: 31.10.2019 Статья принята к печати: 18.11.2019 Опубликована онлайн: 07.12.2019 DOI: 10.24075/vrgmu.2019.076

Placental insufficiency (PI) and the ensuing pregnancy complications, including intrauterine growth restriction (IUGR) and pre-eclampsia, are clinical manifestations of impaired placental perfusion. The mechanisms implicated in PI involve abnormal placental angiogenesis and villous maldevelopment caused by: 1) insufficient trophoblast invasion: 2) incomplete remodeling of spiral arteries; 3) imbalance between pro- and antiangiogenic factors; 4) maternal coagulation defects [1]. Therefore, research into PI etiology should be focused on the potential role of multifunctional regulatory systems, including the urokinase system, as contributors to the defects described above. The urokinase system consists of the urokinase-type plasminogen activator (uPA), its main substrate (plasminogen), plasminogen activator inhibitors (PAI-1, PAI-2), and the uPA receptor (uPAR); the latter regulates and improves the efficacy of urokinase-mediated proteolysis by binding to uPA [2]. The urokinase system can trigger a variety of signaling cascades and thereby transform the cellular environment through proteolysis of the extracellular matrix, as well as induce cell migration and proliferation in response to such transformations [3].

Almost all components of the urokinase system have genetic polymorphisms that affect uPA activity or the level of its expression. Today, there is sufficient evidence confirming the role of some of those genetic variants in promoting pregnancy complications. So far, associations between such polymorphisms and PI have been best studied for PAI-1. For example, the indel mutation in the *SERPINE1* promoter (–675 5G/4G) has been reliably linked to early pregnancy loss/preeclampsia [4, 5].

Polymorphisms of the urokinase and urokinase receptor genes are less studied. In this article, we investigate possible associations between PI and 4 SNPs: 2 of the PLAU gene (rs4065, rs2227564) and another 2 of the PLAUR gene (rs344781, rs2302524). PLAU rs4065 C/T 3'-UTR is a C/T substitution in the noncoding gene region resulting in enhanced mRNA stability and hence aberrant uPA levels [6]. PLAU Pro141Leu (rs2227564) results in the increased hydrophobicity of the kringle domain, which reduces uPA affinity to fibrin and possibly the components of the extracellular matrix [7]. Although the role of the urokinase kringle domain is not fully clear, this polymorphism can alter urokinase activity. PLAUR rs2302524 (A659G) is another missense mutation that presumably affects the activity of the urokinase system [8]. PLAUR rs344781 affects the activity of the PLAUR promoter; the T allele enhances transcription [9]. Considering the significance of assessing both maternal and fetal components of the mother-placenta-fetus system, we analyzed the genotypes of the mother and the fetus. Genotyping data were compared to the results of a histopathological examination of placental specimens so as to determine the effect of gene polymorphisms on placental tissue morphology and the expression of urokinase system proteins. The aim of this work was to study the associations between PI and SNPs in the genes coding for the components of the uPA-uPAR-system, as well as their effects on the intensity of protein expression in placental tissue and placental morphology.

METHODS

The study was conducted at the Medical Research and Educational Center of Lomonosov Moscow State University in 2018. Samples of venous blood, placental tissue and umbilical cords, as well as clinical data, were obtained from the Center's Biobank. Originally, the samples had been collected from 162 female patients aged 20 to 49 years and 95 newborns immediately after delivery.

The control group consisted of 114 healthy women with uncomplicated pregnancy and delivery. The PI group included 48 patients with early pre-eclampsia (< 34 weeks into gestation) and/or early grade II-III IUGR (< 32 gestational weeks), IUGR was diagnosed based on a biometric lag of 2 weeks; the actual gestational age was inferred from the first day of the last menstrual period and from the findings of the early ultrasound scan. Pre-eclampsia was defined as elevated systolic $BP \ge 140$ mmHg and diastolic $BP \ge 90$ mmHg on at least two occasions after week 20 into gestation in the presence of at least one of the following signs: proteinuria \geq 300 mg/day, renal failure (hypercreatininemia \geq 90 µmol/L), liver dysfunction (ALT or AST > 40 IU/L), impaired blood flow in the motherplacenta-fetus system on the Doppler scan, thrombocytopenia 150,000/µL, and neurological symptoms. The exclusion < criteria were as follows: multifetal pregnancy, Rh-sensitization, gestational diabetes mellitus, severe extragenital pathology, drug abuse, smoking, fetal abnormalities or genetic disorders. All pregnancies were spontaneous. In order to exclude "small for gestational age" fetuses from the study, a Doppler scan of the umbilical artery was performed. Women with normal blood flow parameters were excluded.

Umbilical cord samples were collected from 60 newborns in the PI group (pregnancies complicated by pre-eclampsia and/ or IUGR) and 35 newborns in the control group (uncomplicated pregnancies and delivery). For the analysis, we selected umbilical cord fragments located 8-10 cm away from the placenta. The samples were fixed in 10% formalin or frozen at -80 °C. In 53 cases (25 patients with PI and 28 controls), we collected samples of maternal blood, umbilical cord fragments and placental tissue. For each mother-newborn pair, 3 fragments of seemingly healthy tissue sized $1 \times 0.5 \times 0.5$ cm were collected from the peripheral, paracentral and central areas of the placenta; the fragments were fixed in 10% buffered formalin for 12 h; then the samples were dehydrated and embedded in paraffin. All placenta donors in the PI group gave birth by Caesarian section at >28 weeks gestation (2 patients before gestational week 34; 6 patients after week 34); in the control group, the babies were delivered at term.

Genotyping

DNA was isolated from K₂ EDTA-containing peripheral maternal blood using a QIAmp DNA Blood Mini Kit and from umbilical cord fragments using a DNeasy Blood and Tissue Kit (QIAGEN; Germany) following the manufacturer's protocol. (the minimum sample weight of 25 mg and prolonged overnight lysis).

PLAU C/T 3'-UTR (rs4065) and *PLAUR* T(-516)C (rs344781) polymorphisms were detected by real-time PCR. Amplification was performed in a RotorGene Q thermocycler (QIAGEN; Germany). Allele-specific hydrolyzed probes were used. The following primers and probes were used:

rs4065_F: 5'-TGGTTGTCATTTTTGCAGTAGAGTC-3'; rs4065_R: 5'-GGCCTATGCCTGAGGGTAAAG-3';

rs4065_prC:FAM-5'-AAGCTATTGTCGTTCGCCCTGGTGG-3'-BHQ1; rs4065_prT: HEX-5'-AAGCTATTGTCGTTCACCCTGGTGGG-3'-BHQ1;

rs344781_F: 5'-ATCCTGAAATATGCATCTCTTAAACACT-3'; rs344781_R: 5'-TTAACATTTACCAAGGACCTACTTCG-3'; rs344781_prC:FAM-5'-CACAGCGGGAAGCAAAGCAAGGGT-3'-BHQ1;

rs344781_prT:HEX-5'-CACAGCAGGAAGCAAAGCAAGGGT-3'-BHQ1). *PLAU* C/T 7240 (rs2227564), *PLAUR* A659G (rs2302524) and SERPINE1 -675 5G/4G polymorphisms were detected by real-time PCR using commercial kits for SNP detection (DNA-Technology; Russia).

Morphometry and immunohistochemistry

Four-µm thick sections were prepared from paraffin blocks and mounted on Polysine Slides (Menzel GmbH & Co KG; Germany). Dewaxing, rehydrating and epitope retrieval were performed using Dewax and HIER BufferM (pH 8.0) (Thermo; UK) at 95-98 °C for 20 min in the pre-treatment PT-Module (Thermo; UK). Immunohistochemistry reactions were carried out in a Thermo Scientific LabVision Autostainer 480S (Thermo; UK). The sections were incubated with 1:150 monoclonal rabbit anti-uPA antibodies (ab133563) and 1 : 100 polyclonal rabbit anti-uPAR antibodies (ab103791) (Abcam; UK) for 30 min. A chromogenic (DAB) Ultra Vision Quanto Detection System (Thermo; UK) was used to detect staining. Then, the sections were treated with hematoxylin (1-3 min) and covered with a cover-glass. The slides were examined under a Leica DM 1000 microscope equipped with an HI PLAN 40×/0.65 ∞/0.17/0FN25 lens and a digital high-resolution camera Leica DMC 2900; the images were processed in Leica Application Suite 8.0 (Leica; Germany). A total of 1,060 microphotographs were taken: 530 for uPAR-treated and 530 for uPA-treated slides.

Image processing

On each image, an area of 7×7 pixels was selected in the background outside the specimen; this area was assigned an average color value of all the pixels it contained. This average value was used to white-balance the image, so that the corrected color would be white. As a result, the background on all images appeared very close to white and all microphotographs did not differ in color tones. After color normalization, large clusters of red blood cells and artifacts were manually selected and removed on each photograph. All images were resized to 1024 \times 768 pixels.

Measured parameters

Using ImageJ, v1.51s (National Institutes of Health; USA), we calculated the villi surface area (mm²) and the area occupied by the intervillous space (mm²) for each image. To estimate the vessel surface area (% of the villi surface area), the stroma-to-vessel ratio and the intensity of uPA/uPAR expression in the villi, blood vessels were highlighted manually. The stroma-to-vessel ratio was determined by the formula: vessel surface area / (villi surface area — vessel surface area). All parameters were calculated as a geometric mean from 10 processed images per section.

Measurement of marker expression intensity

To estimate the intensity of uPA and uPAR expression, the ImageJ color threshold function was applied to the areas representing villi on the images. The following parameters were used: hue [0;37], saturation [46;255] and brightness [62;251], as they allow detecting a vast variety of brown tones. The selected areas were converted into black and white to evaluate pixel color intensity. Purely black pixels were assigned the value of 255, whereas purely white pixels, 0. All pixels outside the villi or those outside the specified color range were assigned a 0 value. The mean color value was calculated for each image based on non-white pixels (color $\!\neq\!0$). Expression intensity was calculated by the formula:

$$INT = \frac{\sum_{c=0}^{255} c \times N_c}{V_i \times 1024 \times 768}$$

where INT is intensity; *c* is the mean color value for non-white pixels; *N* is the number of pixels with the specific c; *V* is the area of the image occupied by the villi expressed in the range from 0 to 1. The yielded values can be interpreted as uPA/uPAR expression intensity in the range from 0 (no expression) to 255 (maximum expression) providing that staining of the villi is uniform.

Statistical analysis

Statistical analysis was conducted in RStudio v1.1.453 and the SNP Stats web tool [10] developed for the analysis of genetic polymorphism data. The Akaike information criterion was used to choose the type of inheritance model (codominant, dominant, recessive, overdominant, or log-additive). We selected models with the lowest AIC indicating better goodness of fit in the presence of fewer parameters. Continuous variables were tested for normality using the Shapiro-Wilk test. Differences between the groups were assessed using Student's t-test, one-way ANOVA for parametric data, the Wilcoxon rank-sum test, or the Tukey test for nonparametric data depending on the number of groups, the Kruskal-Wallis test. Categorical variables were assessed using the χ^2 test. Odds ratios for the risk of PI were also calculated. Univariate binary logistic regression models were used to construct 95% CI and estimate OR pointwise. Statistical weight and significance of individual genotypes were analyzed using logistic regression. Differences were considered significant at p < 0.05.

RESULTS

Table 1 shows frequencies of maternal and fetal SNPs significantly associated with the risk of PI (corrected to maternal age). Associations have been established between PI and the following alleles: the maternal C allele PLAU rs4065, the maternal A allele PLAUR rs2302524, the fetal C allele PLAU rs4065, and the fetal C allele PLAUR rs344781. To study the effects of both maternal and fetal genotypes, we built a model in which PI was the dependent variable and maternal and fetal genotypes were predictors (the presence of 2 mutant alleles scored 2 points, heterozygous variants scored 1 point, and the presence of 2 referent alleles scored 0). Then, we estimated the statistical significance of the predictors, their weight and effect (positive or negative). Characteristics of the model are provided in Table 2; a statistically significant effect was demonstrated for the fetal PLAU rs4065 polymorphism: the C to T substitution was protective against PI, i.e. reduced its probability; TT was the most prognostically favorable genotype.

In the control group samples, villous tree architecture was normal, dominated by terminal villi with sinusoidally dilated capillaries and showing an intimate contact between the trophoblastic surface and the vascular wall underneath. In the PI group, a variety of histopathologic phenomena were observed. In some cases, nonbranching angiogenesis prevailed presenting as the lack of terminal villi, small villous diameter and the absence of syncytial knotting. In 16 cases, an excessive compensatory placental response was observed, including angiomatosis of the villi, extensive syncytial knotting in the aggregated terminal villi and the narrowing of the intervillous space. These findings were fortified by the estimates of

ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ І МЕДИЦИНСКАЯ ГЕНЕТИКА

the villi surface area and the intervillous space (Table 3). No differences were found between the PI and control groups in the vessel surface area and the stroma-to-vessel ratio (Table 3), which may be explained by the morphological heterogeneity observed in patients with preeclampsia and IUGR, as well as by the difference in gestational age at delivery. examination of the placenta (morphometric parameters and the immunohistochemical expression of uPA and uPAR). The intensity of uPA/uPAR expression in syncytiotrophoblasts exceeded that in the stromal cells and the endothelium of villous vessels (Fig. 1 A–D). The intensity of uPA expression was reliably lower in the placental tissue of patients with PI ($\rho = 0.033$) (Table 3; Fig. 1A–B); no difference in uPAR expression was observed between the groups (Table 3; Fig. 1C–D).

The data yielded by genotyping of maternal and fetal specimens were compared to the results of the microscopic

 $\label{eq:table_$

PLAURINGUECC23.103.0312.02.08-51.03 A_{AP} $AP_APA_{AP}AP_APA_{AP}AP_APA_{AP}AP_APA_{AP}AP_APA_{AP}AP_APA_{AP}AP_APA_{AP}AP_APA_{AP}AP_APAP_APA_{AP}AP_AP$		Inheritance model	Inheritance model Genotype PI, % (n) Control % (n) OR (CI 95%)*		p	AIC		
PLAU rs4085 CC 23.1 (s) 3.8 (s) 12.90 (2.88–51.68) 0.001 120.9 PLAU rs4085 CT 41 (16) 21.8 (17) 5.46 (194–137) 0.001 120.9 PLAU rs4085 CT 64.1 (25) 25.6 (20) 6.83 (2.83–17.79) -0.001 120.1 CC 73.1 (s) 3.8 (s) 6.97 (1.58–3.08) 0.001 130 CC 73.1 (s) 3.8 (s) 6.97 (1.58–3.08) 0.001 111 Overdominant CC 73.1 (s) 3.8 (s) 6.97 (1.58–3.08) 0.001 119.5 ACC 77.7 75.9 (30) 96.2 (7) 1 0.001 119.5 Additive - - - 4.14 (2.02–5.51) <0.001	maternal SNP							
CodominantC/T41 (16)21.8 (17)5.46 (1.94-15.37)0.001120.9T/T35.9 (14)7.44 (68)1 </td <td rowspan="8"><i>PLAU</i> rs4065</td> <td rowspan="3">Codominant</td> <td>C/C</td> <td>23.1 (9)</td> <td>3.8 (3)</td> <td>12.90 (2.68–51.68)</td> <td></td> <td></td>	<i>PLAU</i> rs4065	Codominant	C/C	23.1 (9)	3.8 (3)	12.90 (2.68–51.68)		
PLAU rs408 Image: constraint of the section of the secti			C/T	41 (16)	21.8 (17)	5.46 (1.94–15.37)	0.0001	120.9
PLAU mAMOSControl TTCT-C/C64.1 (25)25.6 (20)6.6.3 (2.6.3-17.79) (1-0.001Pl2.1RecessiveTTGC/C32.1 (9)38.13)6.6.7 (1.5.8-0.06) (10.00610PLAU mAMOSC/CT76.9 (30)96.2 (7.5)11006100OverdominantC/CT96.9 (3.6)3.6.403.6.400.00111.9Additive4.14 (2.02-8.51)<0.0011			T/T	35.9 (14)	74.4 (58)	1]	
PLAU rs4065 Continuant Tr 35.9 (1.4) 74.4 (5.9) 1 Count L2.1 Recessive C/C 23.1 (9) 3.8 (3) 6.97 (1.58-0.69) 0.000 100 Overdominant C/C 41 (16) 21.8 (17) 3.46 (133-0.03) 0.001 119.5 Additive - - - 4.14 (2.02-6.51) <0.001			C/T–C/C	64.1 (25)	25.6 (20)	6.83 (2.63–17.79)	-0.0001	120.1
PLAU ISHUDRecessiveC/C23.1(9)3.8 (3)6.97 (1.58-30.68) (1.1 (1.58-30.68)		Dominant	T/T	35.9 (14)	74.4 (58)	1	<0.0001	
Indeside TT-Cr 76.9 (40) 98.2 (75) 1 0.000 133 Overdominant C/C-T/T 59 (20) 78.2 (61) 1 0.01 131 Additive - - - 4.14 (202-8.51) <0.001		Recessive	C/C	23.1 (9)	3.8 (3)	6.97 (1.58–30.68)	0.006	130
Overdominant C/C-T/T 59 (23) 78.2 (61) 1 0.1 1.1 Additive - 41 (10) 21.8 (17) 3.46 (1.3.9.0.03) <0.000			T/T–C/T	76.9 (30)	96.2 (75)	1	0.000	
Crd Crd 41 (16) 21.8 (17) 3.46 (1.33-9.03) 0.01 131 Additive - - - - 0.414 (2.02-6.10) 0.0001 119.5 Additive - - - 0.144 (2.02-6.10) 0.0001 119.5 Additive A/A 79.5 (31) 51.9 (42) 1 0.02 0.001 133.7 AGG 51.9 (42) 9.9 (9) 0.30 (0.05-0.69) 0.02 1 0.005 131.8 A/AG 79.5 (31) 51.9 (42) 1 0.005 1 0.005 131.8 A/AG 94.9 (37) 90.1 (73) 1 0.016 1 0.018 131.8 A/AGG 84.6 (33) 61.7 (50) 0.43 (0.09-2.41) 0.31 138.5 Additive - - - 0.39 (0.10.10.67) 0.31 132.9 Additive - - - 0.39 (0.10.29-2.10) 0.018 92.8 PLAU rstoff Additive - -		Overdeminant	C/C-T/T	59 (23)	78.2 (61)	1	0.01	131
IndexImage: constraint of the set of the		Overdominant	C/T	41 (16)	21.8 (17)	3.46 (1.33–9.03)	0.01	
PLAUR rs2022 AVA 79.5 (31) 51.9 (42) 1 AGG 15.4 (6) 38.3 (31) 0.27 (0.09-0.77) 0.02 13.7 PLAUR rs202242 AVA 79.5 (31) 51.9 (42) 0.10 0.00 0.01 13.8 PLAUR rs202242 AVA 79.5 (31) 51.9 (42) 0.10 0.005 13.8 PLAUR rs202242 AVA 79.5 (31) 51.9 (42) 0.10 0.005 13.8 PLAUR rs202242 AVA-A/G 94.9 (37) 90.17(3) 1 0.005 13.8 PLAUR rs20224 AVA-A/G 94.9 (37) 90.17(3) 1 0.011 13.8 AVA-A/G 15.4 (6) 38.3 (31) 0.0110-0.87 0.11 13.8 AVA-A/G 15.4 (6) 38.3 (31) 0.0110-0.87 0.01 13.2 Additive - - - 0.39 (0.18-0.85) 0.01 13.2 PLAU rs4056 Codominant C/C 77.7 23.6 (33) 30.4 (7) 1 0.93 0.039		Additive	-	-	-	4.14 (2.02–8.51)	<0.0001	119.5
A/G 15.4 (é) 38.3 (3) 0.27 (0.09-0.77) 0.02 13.37 Q/A 70.5 (1) 9.9 (6) 0.30 (0.0-0.67) - - Dominant A/A 79.5 (3) 51.9 (2) 1 - - - - - - - - - - - - - 0.00 - - - - 0.01 - - - 0.01 - - - 0.01 - - - 0.01 0.01 10.01 - - - 0.01 0.01 10.01 10.01 - - - 0.01 0.01 10.01 10.01 - - 0.01 0.01 10.01 - - 0.01 10.01 - - 0.01 0.01 10.01 - - - 0.01 0.01 10.01 - - - 0.01 0.01 - - - 0.01 0.01 -			A/A	79.5 (31)	51.9 (42)	1		
PLAUR rs20254 Image: formation of the state		Codominant	A/G	15.4 (6)	38.3 (31)	0.27 (0.09–0.77)	0.02	133.7
PLAUR rs230254 AA 79.5 (31) 51.9 (42) 1 0.005 131.8 $PLAUR rs230254$ AG AG 20.5 (8) 48.1 (39) 0.27 (0.1-0.7) 0.01 1 $Recessive$ AG 94.9 (37) 90.1 (73) 1 0.31 138.5 $G(G$ 5.12 9.90 (37) 90.1 (30) (0.43 (0.08-2.1)) 0.31 0.31 138.5 $Overdominant$ $A/A-G/G$ 84.6 (33) 61.7 (50) 1 0.018 132.9 $Additive$ $ 0.39$ (0.18-0.85) 0.01 132.9 $Recessive$ C/C 39.17 4.3 (1) 8.25 (0.88-77.21) 0.031 132.9 $PLAUr s4065$ $COdominant$ C/C 30.9 (7) 4.3 (1) 8.25 (0.88-77.21) 0.031 9.7 $PLAUr s4065$ $COdominant$ C/C 76.4 (42) 89.6 (16) 1.37 (0.45-4.17) 0.031 9.7 $PLAUr s4065$ C/C 76.4 (42) 89.6 (16) 1.37 (0.45-4.17) 0.039 9.7 $PLAUr s4065$ C/C 76.4 (42) 89.6 (16) 1.37 (0.45-4.17) 0.039 9.7 $PLAUr s4065$ $C/C - 7/C$ 76.4 (42) 89.6 (16) 1.37 (0.45-4.17) 0.039 9.7 $PLAUr s4065$ $C/C - 7/C$ 76.4 (42) 89.6 (16) $1.90.99.2-4.29$ 0.073 9.7 $PLAUr s4065$ $C/C - 7/C$ 76.4 (42) 69.2 (15) $0.71.1$ 0.049 $1.17.9$ $PLAUr s4065$ $C/C - 7/C$ 76.4			G/G	5.1 (2)	9.9 (8)	0.30 (0.05–0.68)		
PLAUR rs2302524 Image: constraint of the section of the sectin of the section of the section of the section of the s		Dominant	A/A	79.5 (31)	51.9 (42)	1	0.005	101.0
PLAUR IS2302342 Recessive AVA-A/G 94.9 (37) 90.1 (73) 1 0.31 138.5 Qverdominant AVA-A/G 84.6 (33) 61.7 (50) 1 0.018 134 Additive - - 0.39 (0.18-0.85) 0.01 132.9 Additive - - 0.39 (0.18-0.85) 0.01 132.9 Verdominant A/G 30.9 (17) 4.3 (1) 8.25 (0.88-77.21) 0.031 132.9 Codominant C/T 455 (25) 65.2 (15) 0.91 (0.29-2.17) 0.031 92.8 PLAU rs4065 C/T 455 (25) 65.2 (15) 0.91 (0.29-2.17) 0.031 92.8 PLAU rs4065 C/T 7.77 23.6 (13) 30.4 (7) 1 95.8 PLAU rs4065 C/C 7.77 23.6 (13) 30.4 (7) 1 0.031 92.8 PLAU rs4065 C/C 30.9 (17) 4.3 (1) 8.82 (1.09-71.67) 0.039 9.7.4 PLAU rs4065 C/C/C 7.77 23.6 (13)		Dominant	A/G–G/G	20.5 (8)	48.1 (39)	0.27 (0.1–0.71)	0.005	131.0
Indecisive G/G 5.1 (2) 9.9 (8) 0.43 (0.08-2.41) 0.51 185.3 Overdominant A/A-G/G 84.6 (33) 61.7 (50) 1	FLAUN 152302324	Pagagaiya	A/A–A/G	94.9 (37)	90.1 (73)	1	0.21	129.5
NA-G/G 84.6 (3) 61.7 (50) 1 0.018 34.4 A/G 15.4 (6) 38.3 (31) 0.31 (0.11-0.87) 0.018 132.9 Additive - - 0.39 (0.18-0.85) 0.01 132.9 Image: Company of the image: Com		necessive	G/G	5.1 (2)	9.9 (8)	0.43 (0.08–2.41)	0.31	138.5
A/G 15.4 (6) 38.3 (31) 0.31 (0.11-0.87) 0.018 134 Additive - - - 0.39 (0.18-0.85) 0.01 132.9 fetal SNP Codominant C/C 30.9 (17) 4.3 (1) 8.25 (0.88-77.21) 0.031 92.8 Codominant C/C 30.9 (17) 4.3 (1) 8.25 (0.88-77.21) 0.031 92.8 Codominant C/T 45.5 (25) 65.2 (15) 0.91 (0.29-2.87) 0.031 92.8 PLAUrs4055 Codominant C/T 45.5 (25) 65.2 (15) 0.91 (0.29-2.87) 0.031 92.8 PLAUrs4056 C T/T 23.8 (13) 30.4 (7) 1 0.031 97.4 PLAUrs4056 C/C 30.9 (17) 4.3 (1) 8.82 (1.09-71.67) 0.031 91.4 PLAUrs4056 Processive C/C 30.9 (17) 4.3 (1) 8.82 (1.09-71.61) 0.031 91.4 PLAUrs4056 Processive C/C 45.5 (25) 65.2 (15) 0.47 (0.17-1.31) <td></td> <td>Quardaminant</td> <td>A/A–G/G</td> <td>84.6 (33)</td> <td>61.7 (50)</td> <td>1</td> <td>0.019</td> <td rowspan="2">134</td>		Quardaminant	A/A–G/G	84.6 (33)	61.7 (50)	1	0.019	134
Additive0.39 (0.18-0.85)0.01132.9fetal SNPFetal SNPFetal SNPCOCO30.9 (7)4.3 (1)8.25 (0.88-77.21)0.03192.8COdominantC/T45.5 (25)66.2 (15)0.91 (0.29-2.87)0.03192.8T/T23.6 (13)30.4 (7)10.03192.8DominantC/T-C/C76.4 (42)69.6 (16)1.37 (0.45-4.17)0.1897.4T/T23.6 (13)30.4 (7)10.189.797.8PLAUR StableC/T-C/C76.4 (42)69.6 (16)1.37 (0.45-4.17)0.01997.4T/T23.6 (13)30.4 (7)10.01997.4Outerion (17.7)69.1 (38)95.7 (22)10.1191.4Outerion (17.7)69.1 (38)95.7 (23)10.47 (0.17-1.31)0.1491.6Outerion (17.7)69.1 (38)95.7 (23)1.047 (0.17-1.31)0.1491.6Outerion (17.7)54.5 (25)65.2 (15)0.047 (0.17-1.31)0.1491.6Outerion (17.7)23.6 (13)30.4 (7)10.01811.1Outerion (17.6)1.100.01811.1Outerion (17.6)30.9 (17)4.3 (1)2.71 (0.53-13.76)11.1Outerion (17.6)1.010.01813.1Outerion		Overdominant	A/G	15.4 (6)	38.3 (31)	0.31 (0.11–0.87)	0.018	
Head SubsectionPLAU resolutionC/C30.9 (7)4.3 (1)8.25 (0.86-77.21) 0.91 (0.29.2.67)0.031 0.019.0319.031PLAU resolutionC/C45.5 (2)66.5 (15)0.91 (0.29.2.67)0.0319.0319.031PLAU resolutionC/T-C/C76.4 (2)66.6 (16)1.37 (0.45-4.17) 0.010.0580.137 (0.45-4.17) 0.010.0580.0110.0589.011PLAU resolutionC/T-C/C30.9 (7)4.3 (1)8.82 (1.09-71.67) 0.0100.0100.0190.0199.019PLAU resolutionC/C30.9 (7)4.3 (1)8.82 (1.09-71.67) 0.0100.0100.0199.0199.019PLAU resolutionC/C-T/T69.1 (30)95.7 (2)1.10.0199.0199.019PLAU resolutionC/C-T/T54.5 (20)34.8 (8)1.10.0199.0199.019PLAU resolutionC/C-T/T54.5 (20)34.8 (8)1.10.0139.0149.014PLAU resolutionT/CVVV1.0110.01811.01PLAU resolutionT/CVS6.2 (15)0.49 (0.11-0.71)0.01813.14PLAU resolutionT/CVVVV1.010.01811.01PLAU resolutionT/CVVVVVV1.011.0111.01PLAU resolutionT/CVVVVVVVVVPLAU resolutionT/C		Additive	-	-	-	0.39 (0.18–0.85)	0.01	132.9
$PLAU rs4065 \\ \hline \\ PLAU rs4065 \\ \hline \\ PLAU rs4065 \\ \hline \\ PLAU rs4065 \\ \hline \\ \hline \\ PLAU rs4065 \\ \hline \\ \hline \\ PLAU rs4065 \\ \hline \\ \hline \\ \\ PLAU rs4065 \\ \hline \\ \hline \\ \\ PLAU rs4065 \\ \hline \\ \\ \hline \\ \\ PLAU rs4065 \\ \hline \\ \\ \hline \\ \\ PLAU rs4065 \\ \hline \\ \\ \hline \\ \\ PLAU rs4065 \\ \hline \\ \\ \hline \\ \\ PLAU rs4065 \\ \hline \\ \\ \hline \\ \\ PLAU rs4065 \\ \hline \\ \\ \hline \\ \\ PLAU rs4065 \\ \hline \\ \\ \hline \\ \\ \\ PLAU rs4065 \\ \hline \\ \\ \hline \\ \\ \\ PLAU rs4065 \\ \hline \\ \\ \\ \hline \\ \\ \\ PLAU rs4065 \\ \hline \\ \\ \\ \hline \\ \\ \\ PLAU rs4065 \\ \hline \\ \\ \\ \hline \\ \\ \\ \\ PLAU rs4065 \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $				fetal SNP				
$PLAU rs4065 \begin{array}{c c c c c c c c c c c c c c c c c c c $		Codominant	C/C	30.9 (17)	4.3 (1)	8.25 (0.88–77.21)		92.8
$ \begin{array}{ c c c c c c } \hline $\Gamma/$T$ $23.6 (13) $30.4 (7) 1 1 1 1 1 1 1 1 1 1			C/T	45.5 (25)	65.2 (15)	0.91 (0.29–2.87)	0.031	
$ \begin{array}{ c c c c c c } PLAU \mbox{ rs} 4065 \\ \hline \mbox{ PLAU \mbox{ rs} 4065 } \\ \hline \mbox{ Recessive } \\ \hline \mbox{ rs} C/C & 30.9 (17) & 4.3 (1) & 8.82 (1.09-71.67) & \\ \hline \mbox{ rs} 1 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.009 & 0.007 & 0.009 & 0.007 & 0.009 & 0.007 & 0.007 & 0.009 & 0.007 & 0.$			T/T	23.6 (13)	30.4 (7)	1	1	
PLAU rs4065 Image: constraint of the constra		Dominant	C/T–C/C	76.4 (42)	69.6 (16)	1.37 (0.45–4.17)	0.59	97.4
$ \frac{PLAUrs4065}{PLAUrs4065} = \frac{C/C}{Recessive} = \frac{C/C}{T/T-C/T} = \frac{3.0.9(17)}{6.9.1(38)} = \frac{4.3(1)}{9.5.7(22)} = \frac{8.82(1.09-71.67)}{1} \\ - \frac{0.009}{98} = \frac{9.0.8}{9.0.9} \\ - \frac{C/T}{54.5(30)} = \frac{45.5(25)}{65.2(15)} = \frac{0.47(0.17-1.31)}{0.47(0.17-1.31)} \\ - \frac{0.14}{9.5.5} = \frac{9.5}{9.5.5} \\ - \frac{1.99(0.92-4.29)}{0.073} = \frac{0.073}{94.5} \\ - \frac{1.99(0.92-4.29)}{0.074} = \frac{0.074}{94.5} \\ - 1.99($	DL 411 - 4005	Dominant	T/T	23.6 (13)	30.4 (7)	1	0.56	
Indecessive T/T-C/T 69.1 (38) 95.7 (22) 1 0.009 90.8 Overdominant C/T 45.5 (25) 65.2 (15) 0.47 (0.17-1.31) 0.14 95.5 Additive - - - 1.99 (0.92-4.29) 0.073 94.5 Additive - - - 1.99 (0.92-4.29) 0.073 94.5 Additive - - - 1.99 (0.92-4.29) 0.073 94.5 Codominant T/T 23.6 (13) 30.4 (7) 1 0.014 117.9 Codominant T/C 45.5 (25) 65.2 (15) 0.28 (0.11-0.71) 0.014 117.9 PLAUR rs344781 T/C 45.5 (25) 65.2 (15) 0.28 (0.11-0.71) 0.018 131.4 PLAUR rs344781 T/T 23.6 (13) 30.4 (7) 1 0.098 131.4 PLAUR rs344781 T/T 23.6 (13) 30.4 (7) 1 0.018 128.5 C/C 7/T 54.5 (30) 34.8 (8) 1 <td< td=""><td>PLAU 184005</td><td>Decessive</td><td>C/C</td><td>30.9 (17)</td><td>4.3 (1)</td><td>8.82 (1.09–71.67)</td><td>0.000</td><td rowspan="2">90.8</td></td<>	PLAU 184005	Decessive	C/C	30.9 (17)	4.3 (1)	8.82 (1.09–71.67)	0.000	90.8
$ \begin{array}{ c c c c c c } \hline PLAUR rs344781 \\ \hline \hline Overdominant & \hline C/T & 45.5 (25) & 65.2 (15) & 0.47 (0.17-1.31) \\ \hline Overdominant & \hline C/C-T/T & 54.5 (30) & 34.8 (8) & 1 & 0.14 \\ \hline Overdominant & \hline C/C-T/T & 54.5 (30) & 34.8 (8) & 1 & 0.073 & 94.5 \\ \hline Additive & - & - & - & 1.99 (0.92-4.29) & 0.073 & 94.5 \\ \hline Additive & - & - & - & 1.99 (0.92-4.29) & 0.073 & 94.5 \\ \hline Overdominant & \hline T/T & 23.6 (13) & 30.4 (7) & 1 & 0.078 & 117.9 \\ \hline Overdominant & \hline T/C & 45.5 (25) & 65.2 (15) & 0.28 (0.11-0.71) & 0.018 & 131.4 \\ \hline Overdominant & \hline T/C - C/C & 76.4 (42) & 69.6 (16) & 0.49 (0.21-1.16) & - & \\ \hline Overdominant & \hline T/T & 54.5 (30) & 34.8 (8) & 1 & 0.018 & 128.5 \\ \hline Overdominant & \hline T/C & 0.45.5 (50) & 0.34.8 (8) & 1 & 7e-4 & 122.7 \\ \hline \end{array}$		Recessive	T/T–C/T	69.1 (38)	95.7 (22)	1	0.009	
Overdominant C/C-T/T 54.5 (30) 34.8 (8) 1 0.14 95.3 Additive - - - 1.99 (0.92-4.29) 0.073 94.5 Additive - - - 1.99 (0.92-4.29) 0.073 94.5 Note that the problem of the pr		Overdominant	C/T	45.5 (25)	65.2 (15)	0.47 (0.17–1.31)	0.14	95.5
$ \begin{array}{ c c c c c c } \hline \mbox{Additive} & - & - & - & 1.99(0.92-4.29) & 0.073 & 94.5 \\ \hline \mbox{N} & & & & & & & & & & & & & & & & & & &$			C/C-T/T	54.5 (30)	34.8 (8)	1	0.14	
$PLAUR rs344781 \begin{array}{ c c c c c } \hline & T/T & 23.6 (13) & 30.4 (7) & 1 & \\ \hline & T/C & 45.5 (25) & 65.2 (15) & 0.28 (0.11-0.71) & 0.014 & \\ \hline & T/C & 30.9 (17) & 4.3 (1) & 2.71 (0.53-13.76) & \\ \hline & C/C & 30.9 (17) & 4.3 (1) & 2.71 (0.53-13.76) & \\ \hline & T/T & 23.6 (13) & 30.4 (7) & 1 & 0.098 & 131.4 & \\ \hline & T/C - C/C & 76.4 (42) & 69.6 (16) & 0.49 (0.21-1.16) & \\ \hline & T/C - C/C & 76.4 (42) & 69.5 (16) & 0.49 (0.21-1.16) & \\ \hline & T/C - C/C & 30.9 (17) & 4.3 (1) & 5.02 (1.07-23.6) & \\ \hline & C/C & 30.9 (17) & 4.3 (1) & 5.02 (1.07-23.6) & \\ \hline & Overdominant & C/C - T/T & 54.5 (30) & 34.8 (8) & 1 & 7e-4 & 122.7 & \\ \hline & T/C - C/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C - T/C & 16.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C - T/C & 15.5 (15) & 0.23 (0.00.0 54) & \\ \hline & T/C - C/C - T/C & 15.5 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - C/C - T/C & 15.5 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C & 15.5 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C & 15.5 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C & 15.5 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C - T/C & 15.5 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C - T/C & 0.55 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C - T/C - T/C & 0.55 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C - T/C - T/C & 0.54 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C - T/C - T/C - T/C & 0.54 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C - T/C - T/C - T/C - T/C - T/C & 0.54 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C & 0.54 (15) & 0.52 (10.00.0 54) & \\ \hline & T/C - T/C $		Additive	-	-	-	1.99 (0.92–4.29)	0.073	94.5
$PLAUR rs344781 \begin{array}{ c c c c c c } \hline Ccdominant & \hline T/C & 45.5 (25) & 65.2 (15) & 0.28 (0.11-0.71) \\ \hline C/C & 30.9 (17) & 4.3 (1) & 2.71 (0.53-13.76) \\ \hline \\ \hline \\ Dominant & \hline T/T & 23.6 (13) & 30.4 (7) & 1 & 0.098 & 131.4 \\ \hline \\ \hline \\ T/C - C/C & 76.4 (42) & 69.6 (16) & 0.49 (0.21-1.16) & \hline \\ \hline \\ \hline \\ Recessive & \hline \\ \hline \\ C/C & 30.9 (17) & 4.3 (1) & 5.02 (1.07-23.6) & \hline \\ \hline \\ \hline \\ Overdominant & \hline \\ \hline$	<i>PLAUR</i> rs344781	Codominant	T/T	23.6 (13)	30.4 (7)	1		117.9
C/C 30.9 (17) 4.3 (1) 2.71 (0.53-13.76) PLAUR rs344781 T/T 23.6 (13) 30.4 (7) 1 0.098 131.4 T/C C/C 76.4 (42) 69.6 (16) 0.49 (0.21-1.16) Recessive T/T- T/C 69.1 (38) 95.7 (22) 1 0.018 128.5 C/C 30.9 (17) 4.3 (1) 5.02 (1.07-23.6) Overdominant C/C-T/T 54.5 (30) 34.8 (8) 1 7e-4 122.7			T/C	45.5 (25)	65.2 (15)	0.28 (0.11–0.71)	0.014	
$PLAUR rs344781 \begin{array}{ c c c c c c c c } \hline T/T & 23.6 (13) & 30.4 (7) & 1 & 0.098 & 131.4 \\ \hline T/C - C/C & 76.4 (42) & 69.6 (16) & 0.49 (0.21 - 1.16) & & \\ \hline T/C - C/C & 76.4 (42) & 69.6 (16) & 0.49 (0.21 - 1.16) & & \\ \hline Recessive & T/T - T/C & 69.1 (38) & 95.7 (22) & 1 & 0.018 & 128.5 \\ \hline C/C & 30.9 (17) & 4.3 (1) & 5.02 (1.07 - 23.6) & & \\ \hline Overdominant & C/C - T/T & 54.5 (30) & 34.8 (8) & 1 & 7e-4 & 122.7 \\ \hline T/C & 145.5 (25) & 65.2 (15) & 0.22 (0.00 , 0.54) & & \\ \hline \end{array}$			C/C	30.9 (17)	4.3 (1)	2.71 (0.53–13.76)	-	
Dominant T/C - C/C 76.4 (42) 69.6 (16) 0.49 (0.21-1.16) 1 PLAUR rs344781 T/C - C/C 76.4 (42) 69.6 (16) 0.49 (0.21-1.16) 1		Dominant	T/T	23.6 (13)	30.4 (7)	1	0.098	131.4
T/T- T/C 69.1 (38) 95.7 (22) 1 0.018 128.5 C/C 30.9 (17) 4.3 (1) 5.02 (1.07-23.6) 1 7e-4 122.7 Overdominant T/C 45.5 (30) 34.8 (8) 1 7e-4 122.7			T/C –C/C	76.4 (42)	69.6 (16)	0.49 (0.21–1.16)		-
Recessive C/C 30.9 (17) 4.3 (1) 5.02 (1.07-23.6) Overdominant C/C-T/T 54.5 (30) 34.8 (8) 1 7e-4 122.7		Recessive	T/T- T/C	69.1 (38)	95.7 (22)	1	0.018	128.5
Overdominant C/C–T/T 54.5 (30) 34.8 (8) 1 7e–4 122.7			C/C	30.9 (17)	4.3 (1)	5.02 (1.07–23.6)		
Overdominant		Overdominant	C/C-T/T	54.5 (30)	34.8 (8)	1	7e-4	122.7
1/(1 + 4(1))/(2(1)) = 0.02(1(3)) = 0.022(1(1))(9=0.04)			T/C	45.5 (25)	65.2 (15)	0.22 (0.09–0.54)		
Additive – – – 1 00 (0.57–1.77) 0.99 134 1		Additive	-	-	-	1.00 (0.57–1.77)	0.99	134_1

Note: * - OR (95% CI) adjusted for maternal age.

No associations were established between the studied SNPs in *PLAU* and *PLAUR* and the intensity of protein expression in placental tissue.

The protective effect of the C to T substitution in maternal *PLAU* rs4065 was confirmed by its relationship with the degree of villous vascularization: the vessel surface area (% of the villi surface area) and the stroma-to-vessel ratio varied depending on the genotype (Fig. 2). The maximum vasculature corresponded to the TT genotype (Table 4).

DISCUSSION

The uRA-uPAR system is multifunctional. It exerts fibrinolytic activity, participates in degrading the extracellular matrix, affects the bioavailability of growth factors, and regulates cell migration and proliferation. Once the embryo has been implanted, trophoblast cells start to express urokinase [11], and uPAR expression increases at the cell pole involved in trophoblast invasion; throughout the process, uPA activity is regulated by PAI-1,2. Thus, the urokinase system takes an active part in the modulated trophoblast invasion. Natural killers and macrophages are another source of uPA in the placenta. They ensure remodeling of spiral arteries in the endometrium at trophoblast-independent stages; by interacting with NK and macrophages, uPAR-positive smooth muscle cells and endothelial cells acquire their migration phenotype [12, 13]. The urokinase system (specifically, the cells expressing its protein components) "supervises" formation and degradation of fibrin-type fibrinoid [14]. Proteolysis of the extracellular matrix by serine proteases leads to the release of angiogenic factors from its scaffold, including vascular endothelial growth factor

(VEGF). The interaction between VEGF and its class 2 receptor results in the exposure of the proteolytic uPA–uPAR complex to integrins [15], confirming the role of the urokinase system as a mediator of angiogenic factors and an active participant of angiogenesis in the placenta.

In this study, we attempted to assess the risk of placentaassociated pregnancy complications based on the presence of SNPs in maternal and fetal genes. We were able to demonstrate that the TT genotype of *PLAU* rs4065 was associated with the lowest risk for PI. Considering that in the majority of cases the placental and the fetal genotypes are the same, the fetal T allele should be regarded as more significant. Unfortunately, we could not prove that abnormal uPA levels in the placenta are determined by the SNPs in the corresponding gene, which might be explained by the small sample size. However, the association between the TT genotype and the greater vessel surface area in the villi confirms the observed phenomenon.

Previously uPAR expression in chorionic villi was demonstrated to be higher in females with uncomplicated pregnancies than in those at risk of pregnancy loss [16]. The immunohistochemistry analysis conducted as part of our study revealed that uPAR levels in the placenta did not differ between healthy females and patients with placenta-related pregnancy complications. However, the groups did differ in terms of urokinase expression intensity.

There was no previous solid evidence of the direct effect of rs4065 on the level of uPA expression. Our findings suggest that the TT genotype stimulates cell migration and proliferation, is proangiogenic and reduces the risk of PI. Our observation is confirmed by the fact that this polymorphism increases the risk of tumor growth and enhances tumor angiogenesis. There

Table 2. Parameters of the regression model showing the relationship between the risk of PI and SNPs in the genes encoding urokinase system proteins

	Coefficients of factors	efficients of factors Standard error		р			
Free coefficient	-0.6347	1.4248	-0.445	0.656			
Fetal SNP							
PLAU rs2227564	4.0476	2.4788	1.778	0.075			
SERPINE-1rs1799889	0.1157	1.2417	0.093	0.926			
<i>PLAU</i> rs4065	-3.3538	1.3791	-2.432	0.015			
<i>PLAUR</i> rs344781	2.7448	1.5893	1.727	0.084			
<i>PLAUR</i> rs2302524	0.3755	1.4117	0.266	0.79			
Maternal SNP							
PLAU rs2227564	-1.9485	1.3233	-1.472	0.141			
SERPINE-1rs1799889	-2.276	1.387	-1.641	0.101			
<i>PLAU</i> rs4065	1.8566	0.985	1.885	0.059			
PLAUR rs344781	-0.7773	1.3769	-0.564	0.572			
PLAUR rs2302524	2.0156	1.3489	1.494	0.135			

Table 3. Morphological characteristics and immunohistochemical expression of uPA/uPAR in placental tissue

	Median	p	
	PI	Control	
Villi surface area (mm²)	7.445 (6.852; 7.863)	6.464 (6.213; 7.157)	0.005
Intervillous space (mm ²)	6.621 (6.22; 7.17)	7.611 (6.887; 7.84)	0.007
Vessel surface area (% of villi surface area)	19.55 (16.45; 24.85)	18.2 (14.2; 22.6)	0.326
Stroma-to-vessel ratio	0.206 (0.166; 0.26)	0.178 (0.147; 0.253)	0.462
uPA expression	116.449 (100.496; 128.74)	126.087 (113.761; 139.191)	0.033
uPAR expression	117.59 (96.24; 138.94)	130.42 (107.93; 152.91)	0.351

ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ І МЕДИЦИНСКАЯ ГЕНЕТИКА



Fig. 1. Immunohistochemical expression of uPA (A, B) and uPAR (C, D) in the chorionic villi in the controls (A, C) and the PI group (B, D). Staining of syncytiotrophoblast cells with anti- uPA and anti- uPAR antibodies produces intense coloration in healthy tissue and samples of PI patients (A–D). Placental tissue of patients with PI (A) shows less intense coloration of ssyncytiotrophoblast cells after uPA staining in comparison with the control group (B). No difference was observed in immunohistochemical uPAR expression between the groups (C, D). Scale bar: 25 µm





Fig. 2. The vessel surface area and the stroma-to-vessel ratio for different maternal PLAU rs4065 genotypes. The ends of the box are Q1 and Q3; the vertical line inside the box is the median. The ends of the whiskers: Q1 minus 1.5 IQR; Q3 plus 1.5 IQR. Outliers are represented by dots. Confidence intervals are represented by notches

Table 4. The vessel surface area and the stroma-to-vessel ratio for different maternal PLAU rs4065 genotypes

rs4065 genotype	Vessel surface area, mm ²			Stroma-to-vessel ratio			
	Median	95% CI	p**	Median	95% CI	p**	
CC	0.1655	[0.1461; 0.1849]		0.1715	[0.1524; 0.1907]		
СТ	0.182	[0.1528; 0.2112]	0.0305	0.1804	[0.1485; 0.2123]	0.0265	
ТТ	0.225	[0.1969; 0.2531]		0.2306	[0.1959; 0.2652]		

Note: ** --- the Kruskal-Wallis test applied.

are reports of the significantly increased risk for cancer in the presence of the T allele and the TT genotype [17–19]. At the same time, it is known that high uPA levels in some tumors predict a poor outcome [20]. Besides, the T allele of rs4065 has been linked to Quebec platelet disorder caused by excess fibrinolysis due to elevated uPA content in platelets [21].

CONCLUSIONS

High placental uPA and the fetal TT genotype (*PLAU* rs4065) are protective against the risk of PI. We hope that our findings will expand the potential of noninvasive prenatal screening and predict PI by genotyping fetal DNA for rs4065 *PLAU*.

References

- 1. Benirschke K, Burton GJ, Baergen RN. Pathology of the Human Placenta, 6th ed. Springer, 2012; p. 411.
- Poettler M, Unseld M, Mihaly-Bison J, Uhrin P, Koban F. Binder BR, et al. The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration. Thromb Haemost. 2012; 108 (8): 357–66.
- Tkachuk VA, Plekhanova OS, Parfyonova YV. Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol. 2009; 87 (4): 231–51.
- Khosravi F, Zarei S, Ahmadvand N, Akbarzadeh-Pasha Z, Savadi E, Zarnani A, et al. Association between plasminogen activator inhibitor 1 gene mutation and different subgroups of recurrent miscarriage and implantation failure. J Assist Reprod Genet. 2014; 31 (1): 121–4.
- Zhao L, Bracken MB, DeWan AT, Chen S. Association between the SERPINE1 (PAI-1) 4G/5G insertion/deletion promoter polymorphism (rs1799889) and pre-eclampsia: A systematic review and meta-analysis. Molecular Human Reproduction. 2013; 19 (3): 136–43.
- Tran H, Maurer F, Nagamine Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol. 2003; 23 (20): 7177–88.
- Xu J, Li W, Bao X, Ding H, Chen J, Zhang W, et al. Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction. Clin Sci (Lond). 2010; 119 (8): 353–9.
- Yosrlimoto M, Youichi, Ushiyama Y, Sakaia M, Tamakia S, Hara H, et al. Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure. Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology. 1996; 1293 (1): 83–9.
- Campbell DB, Li C, Sutcliffe JS, Persico AM, Levitt P. Genetic evidence implicating multiple genes in the met receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res. 2008; 1 (3): 159–68.
- Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22 (15): 1928–29.
- 11. Martínez-Hernández MG, Baiza-Gutman LA, Castillo-Trápala A,

Литература

- 1. Benirschke K, Burton GJ, Baergen RN. Pathology of the Human Placenta, 6th ed. Springer, 2012; p. 411.
- Poettler M, Unseld M, Mihaly-Bison J, Uhrin P, Koban F. Binder BR, et al. The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration. Thromb Haemost. 2012; 108 (8): 357–66.
- Tkachuk VA, Plekhanova OS, Parfyonova YV. Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol. 2009; 87 (4): 231–51.
- Khosravi F, Zarei S, Ahmadvand N, Akbarzadeh-Pasha Z, Savadi E, Zarnani A, et al. Association between plasminogen activator inhibitor 1 gene mutation and different subgroups of recurrent miscarriage and implantation failure. J Assist Reprod Genet. 2014; 31 (1): 121–4.
- Zhao L, Bracken MB, DeWan AT, Chen S. Association between the SERPINE1 (PAI-1) 4G/5G insertion/deletion promoter polymorphism (rs1799889) and pre-eclampsia: A systematic review and meta-analysis. Molecular Human Reproduction. 2013; 19 (3): 136–43.
- Tran H, Maurer F, Nagamine Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol. 2003; 23 (20): 7177–88.
- 7. Xu J, Li W, Bao X, Ding H, Chen J, Zhang W, et al. Association

Armant DR. Regulation of proteinases during mouse periimplantation development: Urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9. Reproduction. 2011; 141 (2): 227.

- Lash GE, Otun HA, Innes BA, Percival K, Searle RF, Robson SC, et al. Regulation of extravillous trophoblast invasion by uterine natural killer cells is dependent on gestational age. Hum Reprod. 2010; 25 (5): 1137–45.
- Naruse K, Lash GE, Bulmer JN, Innes BA, Otun HA, Searle RF, et al. The Urokinase Plasminogen Activator (uPA) System in Uterine Natural Killer Cells in the Placental Bed During Early Pregnancy. Placenta. 2009; 30 (5): 398–404.
- Pierleoni C, Castellucci M, Kaufmann P, Lund LR, Schnack Nielsen B, Urokinase receptor is up-regulated in endothelial cells and macrophages associated with fibrinoid deposits in the human placenta. Placenta. 2003; 24 (6): 677–85.
- 15. Breuss JM, Uhrin P. VEGF-initiated angiogenesis and the uPA/ uPAR system. Cell adhesion & migration. 2012; 6 (6): 535–40.
- Liu S, Zheng Q, Cui XY, Dai KX, Yang XS, Li FS, et al. Expression of uPAR in human trophoblast and its role in trophoblast invasion. Int J Clin Exp Pathol [Internet]. e-Century Publishing Corporation; 2015; 8 (11): 14325–34. Available from: https://www.ncbi.nlm. nih.gov/pmc/articles/PMC4713534/.
- Xu Z, Meng L-L, Lin J, Ling Y, Chen S, Lin N. Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis. Onco Targets Ther [Internet]. Dove Medical Press. 2015; 9 (8): 2493–502. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574847/.
- Andreasen P, Kjøller L, Christensen L, Duffy MJ. The urokinasetype plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72 (1): 1–22.
- Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999; 71 (2): 130–5.
- Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. Ireland; 2012 May; 222 (1): 8–14.
- Diamandis M, Paterson AD, Rommens JM, Veljkovic DK, Blavignac J, Bulman DE, et al. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood. 2009; 113 (7): 1543–6.

of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction. Clin Sci (Lond). 2010; 119 (8): 353–9.

- Yosrlimoto M, Youichi, Ushiyama Y, Sakaia M, Tamakia S, Hara H, et al. Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure. Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology. 1996; 1293 (1): 83–9.
- Campbell DB, Li C, Sutcliffe JS, Persico AM, Levitt P. Genetic evidence implicating multiple genes in the met receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res. 2008; 1 (3): 159–68.
- Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22 (15): 1928–29.
- Martínez-Hernández MG, Baiza-Gutman LA, Castillo-Trápala A, Armant DR. Regulation of proteinases during mouse periimplantation development: Urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9. Reproduction. 2011; 141 (2): 227.
- Lash GE, Otun HA, Innes BA, Percival K, Searle RF, Robson SC, et al. Regulation of extravillous trophoblast invasion by uterine natural killer cells is dependent on gestational age. Hum Reprod. 2010; 25 (5): 1137–45.
- 13. Naruse K, Lash GE, Bulmer JN, Innes BA, Otun HA, Searle RF, et

al. The Urokinase Plasminogen Activator (uPA) System in Uterine Natural Killer Cells in the Placental Bed During Early Pregnancy. Placenta. 2009; 30 (5): 398–404.

- 14. Pierleoni C, Castellucci M, Kaufmann P, Lund LR, Schnack Nielsen B, Urokinase receptor is up-regulated in endothelial cells and macrophages associated with fibrinoid deposits in the human placenta. Placenta. 2003; 24 (6): 677–85.
- 15. Breuss JM, Uhrin P. VEGF-initiated angiogenesis and the uPA/ uPAR system. Cell adhesion & migration. 2012; 6 (6): 535–40.
- Liu S, Zheng Q, Cui XY, Dai KX, Yang XS, Li FS, et al. Expression of uPAR in human trophoblast and its role in trophoblast invasion. Int J Clin Exp Pathol [Internet]. e-Century Publishing Corporation; 2015; 8 (11): 14325–34. Available from: https://www.ncbi.nlm. nih.gov/pmc/articles/PMC4713534/.
- 17. Xu Z, Meng L-L, Lin J, Ling Y, Chen S, Lin N. Association between the polymorphisms of urokinase plasminogen activation system

and cancer risk: a meta-analysis. Onco Targets Ther [Internet]. Dove Medical Press. 2015; 9 (8): 2493–502. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574847/.

- Andreasen P, Kjøller L, Christensen L, Duffy MJ. The urokinasetype plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72 (1): 1–22.
- Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999; 71 (2): 130–5.
- Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. Ireland; 2012 May; 222 (1): 8–14.
- Diamandis M, Paterson AD, Rommens JM, Veljkovic DK, Blavignac J, Bulman DE, et al. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood. 2009; 113 (7): 1543–6.